Tetratherix Limited 2026Tissue Spacing FranchiseSUCCESSFUL COMPLETION INDEPENDENTOPTIMATRIX PRECLINICAL EVALUATIONAnchored by ScienceASX Release16 September 2026ASX:TTXHIGHLIGHTSSuccessful completion of the first preclinical performance study for Optimatrix in cataract surgery with a...
Line of sight ophthalmic tissue spacing US revenue
Filed with ASX · · 4 pages · English
Summary by 6ix AI
Tetratherix Limited reports the successful completion of a preclinical evaluation for its Optimatrix product, designed for use in cataract surgery, demonstrating effective intraocular pressure management post-surgery. The study showed that even with the product remaining in the eye, pressure returned to pre-operative levels within a short timeframe, indicating its safety and efficacy. Optimatrix is a fully synthetic ophthalmic viscosurgical device that simplifies surgical procedures by eliminating the need for extensive removal processes.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Earlier from Tetratherix
- Tetratherix Ships First US Polymer, Revenue Begins
- Application for quotation of securities - TTX
- Results Presentation 2026
- Appendix 4E and Annual Report 2026
- Successful Completion $15M Placement
Later from Tetratherix
- Notification regarding unquoted securities - TTX
- Tegenix FDA Review Progress
- Notice of Annual General Meeting/Proxy Form
- Notification of cessation of securities - TTX
- TegenEOS Biologic Pathway
Follow Tetratherix into a list and get an email when it puts out news.
Follow Tetratherix